NCT06399081

Brief Summary

Gangrenous cholecystitis is the most common complication of acute cholecystitis. There is no research using machine learning models to construct predictive diagnostic models for gangrenous cholecystitis.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,006

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Dec 2023

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2023

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2024

Completed
1 day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 2, 2024

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

April 29, 2024

Completed
4 days until next milestone

First Posted

Study publicly available on registry

May 3, 2024

Completed
Last Updated

May 3, 2024

Status Verified

May 1, 2024

Enrollment Period

3 months

First QC Date

April 29, 2024

Last Update Submit

May 1, 2024

Conditions

Outcome Measures

Primary Outcomes (2)

  • pathological diagnosis of patients with cholecystectomy

    Check the patient's pathological report and whether the pathological description contains phenomena such as full layer ischemic necrosis and ulceration of the gallbladder wall. Diagnose as gangrenous cholecystitis or non-gangrenous cholecystitis.

    30 days

  • The predictive performance of diagnostic prediction models

    The predictive diagnosis was obtained by the model and each predictive variable, and the metric (Accuracy, Recall, Precision, F1score) of the model was obtained by comparing with the actual pathological diagnosis.

    through study completion, an average of 4 months

Secondary Outcomes (6)

  • WBC value (10*9/L)

    through study completion, an average of 4 months

  • Alanine transaminase value (ALT, U/L)

    through study completion, an average of 4 months

  • D-dimer value

    through study completion, an average of 4 months

  • Fibrinogen value (g/L)

    through study completion, an average of 4 months

  • BMI (Kg/m2)

    through study completion, an average of 4 months

  • +1 more secondary outcomes

Study Arms (2)

Gangrenous cholecystitis

Defined based on intraoperative findings or pathological diagnosis

Other: Observational

Non-gangrenous cholecystitis

Non-gangrenous cholecystitis, such as chronic cholecystitis, acute cholecystitis, acute attack of chronic cholecystitis

Other: Observational

Interventions

Observational

Gangrenous cholecystitisNon-gangrenous cholecystitis

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The patients admitted to the Second Hospital of Dalian Medical University who were diagnosed with cholecystitis through ICD-9 code recognition and underwent cholecystectomy from January 2015 to May 2023

You may qualify if:

  • patients diagnosed with acute cholecystitis or acute exacerbation of chronic cholecystitis in our hospital and receiving complete clinical treatment in our hospital;
  • performing cholecystectomy;
  • having complete and searchable clinical data, such as patient's age, surgical records, and hospitalization days.

You may not qualify if:

  • previous diagnosis of chronic cholecystitis, this time for elective surgical treatment;
  • previous diagnosis of acute cholecystitis, ultrasound-guided cholecystectomy after elective laparoscopic cholecystectomy;
  • concomitant with other acute biliary and pancreatic system-related diseases, such as obstructive jaundice caused by choledochal stones, acute cholangitis, acute pancreatitis, etc.;
  • exclude patients who combined with other surgery patients such as choledochotomy and lithotripsy, choledochoscopic exploration and lithotripsy, bile-intestinal anastomosis, appendectomy, etc;
  • those with incomplete data

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The Second Hospital of Dalian Medical University

Dalian, Liaoning, 116023, China

Location

Related Publications (3)

  • Wu B, Buddensick TJ, Ferdosi H, Narducci DM, Sautter A, Setiawan L, Shaukat H, Siddique M, Sulkowski GN, Kamangar F, Kowdley GC, Cunningham SC. Predicting gangrenous cholecystitis. HPB (Oxford). 2014 Sep;16(9):801-6. doi: 10.1111/hpb.12226. Epub 2014 Mar 17.

    PMID: 24635779BACKGROUND
  • Yacoub WN, Petrosyan M, Sehgal I, Ma Y, Chandrasoma P, Mason RJ. Prediction of patients with acute cholecystitis requiring emergent cholecystectomy: a simple score. Gastroenterol Res Pract. 2010;2010:901739. doi: 10.1155/2010/901739. Epub 2010 Jun 8.

    PMID: 20631896BACKGROUND
  • Borzellino G, Sauerland S, Minicozzi AM, Verlato G, Di Pietrantonj C, de Manzoni G, Cordiano C. Laparoscopic cholecystectomy for severe acute cholecystitis. A meta-analysis of results. Surg Endosc. 2008 Jan;22(1):8-15. doi: 10.1007/s00464-007-9511-6. Epub 2007 Aug 18.

    PMID: 17704863BACKGROUND

MeSH Terms

Interventions

Watchful Waiting

Intervention Hierarchy (Ancestors)

Outcome Assessment, Health CareOutcome and Process Assessment, Health CareQuality of Health CareHealth Services Administration

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
resident physician

Study Record Dates

First Submitted

April 29, 2024

First Posted

May 3, 2024

Study Start

December 1, 2023

Primary Completion

March 1, 2024

Study Completion

March 2, 2024

Last Updated

May 3, 2024

Record last verified: 2024-05

Data Sharing

IPD Sharing
Will not share

The data where our results derived from were from the Second Hospital of Dalian Medical University. The original data were not publicly available and could only be shared with the permission of the Ethics Committee of the Second Hospital of Dalian Medical University.

Locations